Pramipexole - Restless Leg Syndrome

You are here : Home > Formulary Search > Pramipexole - Restless Leg Syndrome

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green

Formulations :

Immediate release tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Important

Preferred

Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment

Documentation

Evidence Review

Restless leg syndrome - APC Paper - November 2018

PAD Profile

ChemicalSubstance :

Pramipexole

Indication :

Restless Leg Syndrome

Group Name :

Keywords :

dopamine agonists, non-ergot-derived dopamine receptor agonists

Brand Names Include :

Mirapexin

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Pramipexole is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Restless Leg Syndrome.

Committee Recommendations (1)

07 Nov 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Pramipexole is recommended as a FIRST line option for the treatment of Restless Leg Syndrome, as per CKS guidance.

Link to CKS page - https://cks.nice.org.uk/restless-legs-syndrome